BioSpace News Archive

Pegfilgrastim is used to fight infection in patients undergoing chemotherapy by stimulating the body’s production of white blood cells Fresenius Kabi’s first U.S. biosimilar candidate

Under revised terms, AcelRx to acquire Tetraphase for $30.0 million in stock and cash, plus an additional $14.5 million in CVRs Continues to believe Tetraphase acquisition complements AcelRx’s commercial strategy and will deliver long-term shareholder value Co-promotion agreement for XERAVA and DSUVIA proceeding well with teams already integrated

As treatment for coronavirus (COVID-19) becomes a global priority, researchers in Brazil are conducting a clinical trial using Multi Radiance Medical super pulsed laser therapy technology as an adjunctive means to improve critical care for COVID-19 patients.

The Norwegian Academy of Science and Letters today announced the 2020 Kavli Prize Laureates in the fields of astrophysics, nanoscience and neuroscience

Results recently published in the Journal of Cardiovascular Electrophysiology confirm that BIOTRONIK’s unique two-lead CRT-DX system provides equivalent therapy to more conventional three-lead systems.

Centinel Spine®, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced FDA approval for the manufacturing transfer of both the prodisc® C Cervical Total Disc Replacement and prodisc® L Lumbar Total Disc Replacement systems to new strategic vendors.

Leading thrombosis specialists from the International Society on Thrombosis and Haemostasis (ISTH) and World Thrombosis Day (WTD) Steering Committee recommend administering either standard preventative or larger doses of heparin (blood thinning medicine) to combat excessive clotting in all hospitalized COVID-19 patients from the time of hospital admission, unless they have contraindications to those medications.

Transcenta Holding Limited (“Transcenta”), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1 - study (NCT04272944) of MSB2311, an investigational PDL1 targeting antibody with pH dependent and tumor recycling property developed by Transcenta’s subsidiary Mabspace Biosciences (Suzhou)

Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced the closing of its previously announced $5 million registered direct offering.

First nationwide safety task force will help employers prioritize worker safety in a post-pandemic world